Global Kidney Academy - Global Kidney Academy

Global Kidney Academy

Global Kidney Academy

Enhance your nephrology practice with CME and tools focused on kidney medicine.

Popular

Personalized Treatment Strategies for Hyperkalemia: Bridging Evidence and Clinical Practice Needs
Personalized Treatment Strategies for Hyperkalemia: Bridging Evidence and Clinical Practice Needs
MinuteCE®
Personalized Treatment Strategies for Hyperkalemia: Bridging Evidence and Clinical Practice Needs
Ellie Kelepouris, MD, FACP, FAHA
1.00 program credit
- Ellie Kelepouris, MD, FACP, FAHA
1.00 program credit
Differentiating Oral Potassium Binders: Mechanism, Onset, and Sodium Load
Differentiating Oral Potassium Binders: Mechanism, Onset, and Sodium Load
MinuteCE®
Differentiating Oral Potassium Binders: Mechanism, Onset, and Sodium Load
James Burton, DM, FRCP; Ellie Kelepouris, MD, FACP, FAHA
1.00 program credit
- James Burton, DM, FRCP
- Ellie Kelepouris, MD, FACP, FAHA
1.00 program credit
Hyperkalemia as a Barrier to GDMT: Why “Stopping GDMT” Is Often the Wrong Reflex
Hyperkalemia as a Barrier to GDMT: Why “Stopping GDMT” Is Often the Wrong Reflex
MinuteCE®
Hyperkalemia as a Barrier to GDMT: Why “Stopping GDMT” Is Often the Wrong Reflex
James Burton, DM, FRCP; Nihar R. Desai, MD, MPH
1.00 program credit
- James Burton, DM, FRCP
- Nihar R. Desai, MD, MPH
1.00 program credit
Potassium Binders to Optimize GDMT Therapy in HFrEF
Potassium Binders to Optimize GDMT Therapy in HFrEF
MinuteCE®
Potassium Binders to Optimize GDMT Therapy in HFrEF
Nihar R. Desai, MD, MPH; Ellie Kelepouris, MD, FACP, FAHA
1.00 program credit
- Nihar R. Desai, MD, MPH
- Ellie Kelepouris, MD, FACP, FAHA
1.00 program credit
FINE-ONE Across the Ages: Evaluating nsMRA Evidence in CKD and Type 1 Diabetes
FINE-ONE Across the Ages: Evaluating nsMRA Evidence in CKD and Type 1 Diabetes
Nephrology
FINE-ONE Across the Ages: Evaluating nsMRA Evidence in CKD and Type 1 Diabetes
Katherine Tuttle, MD
- Katherine Tuttle, MD
The Hidden Danger of IgAN: Pathogenesis and Unmet Needs
The Hidden Danger of IgAN: Pathogenesis and Unmet Needs
MinuteCE®
The Hidden Danger of IgAN: Pathogenesis and Unmet Needs
Jonathan Barratt, MD, PhD
1.00 program credit
- Jonathan Barratt, MD, PhD
1.00 program credit
MinuteCE®
Decoding IgA Nephropathy: From Suspicion to Solution
Jonathan Barratt, MD, PhD; Chee Kay Cheung, MBChB, MRCP, PhD
1.00 credit 8 episodes
- Jonathan Barratt, MD, PhD
- Chee Kay Cheung, MBChB, MRCP, PhD
- An De Vriese, MD, PhD
- Jörg Latus, MD
1.00 credit 8 episodes
Unmasking IgAN: Achieving Earlier Diagnosis
Unmasking IgAN: Achieving Earlier Diagnosis
MinuteCE®
Unmasking IgAN: Achieving Earlier Diagnosis
Jonathan Barratt, MD, PhD; An De Vriese, MD, PhD
1.00 program credit
- Jonathan Barratt, MD, PhD
- An De Vriese, MD, PhD
1.00 program credit

Programs

MinuteCE®
The Potassium Shift: Individualizing Hyperkalemia Management With Modern Oral Potassium Binders
James Burton, DM, FRCP; Nihar R. Desai, MD, MPH
1.00 credit 8 episodes
- James Burton, DM, FRCP
- Nihar R. Desai, MD, MPH
- Ellie Kelepouris, MD, FACP, FAHA
- Pauline A. Swift, PhD
1.00 credit 8 episodes
The Edema Question: Selecting a Potassium Binder in Patients With HF or Congestion
The Edema Question: Selecting a Potassium Binder in Patients With HF or Congestion
MinuteCE®
The Edema Question: Selecting a Potassium Binder in Patients With HF or Congestion
Nihar R. Desai, MD, MPH; Pauline A. Swift, PhD
1.00 program credit
- Nihar R. Desai, MD, MPH
- Pauline A. Swift, PhD
1.00 program credit
INFINITY in Focus: Translating New Nonsteroidal MRA Evidence Into Cardiorenal Practice
INFINITY in Focus: Translating New Nonsteroidal MRA Evidence Into Cardiorenal Practice
Nephrology
INFINITY in Focus: Translating New Nonsteroidal MRA Evidence Into Cardiorenal Practice
Peter Rossing, MD, DMSc
- Peter Rossing, MD, DMSc
Real-World Evidence: Effectiveness of Finerenone in Reducing UACR in Patients With CKD and Type 2 Diabetes
Real-World Evidence: Effectiveness of Finerenone in Reducing UACR in Patients With CKD and Type 2 Diabetes
Nephrology
Real-World Evidence: Effectiveness of Finerenone in Reducing UACR in Patients With CKD and Type 2 Diabetes
Csaba P. Kovesdy, MD
- Csaba P. Kovesdy, MD

CME

From Lab Alert to Action Plan: Monitoring Potassium Without Undermining Cardiorenal Protection
From Lab Alert to Action Plan: Monitoring Potassium Without Undermining Cardiorenal Protection
MinuteCE®
From Lab Alert to Action Plan: Monitoring Potassium Without Undermining Cardiorenal Protection
James Burton, DM, FRCP; Pauline A. Swift, PhD
1.00 program credit
- James Burton, DM, FRCP
- Pauline A. Swift, PhD
1.00 program credit
Proteinuria in IgAN: The Signal, The Target, and the Treatment Goal
Proteinuria in IgAN: The Signal, The Target, and the Treatment Goal
MinuteCE®
Proteinuria in IgAN: The Signal, The Target, and the Treatment Goal
Jonathan Barratt, MD, PhD; An De Vriese, MD, PhD
1.00 program credit
- Jonathan Barratt, MD, PhD
- An De Vriese, MD, PhD
1.00 program credit
Mechanisms Matter! Optimizing Proteinuria Reduction In IgAN
Mechanisms Matter! Optimizing Proteinuria Reduction In IgAN
MinuteCE®
Mechanisms Matter! Optimizing Proteinuria Reduction In IgAN
Chee Kay Cheung, MBChB, MRCP, PhD; Jörg Latus, MD
1.00 program credit
- Chee Kay Cheung, MBChB, MRCP, PhD
- Jörg Latus, MD
1.00 program credit
The Future of IgAN Care
The Future of IgAN Care
MinuteCE®
The Future of IgAN Care
Chee Kay Cheung, MBChB, MRCP, PhD; An De Vriese, MD, PhD
1.00 program credit
- Chee Kay Cheung, MBChB, MRCP, PhD
- An De Vriese, MD, PhD
- Jörg Latus, MD
1.00 program credit